Organization
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute
9 abstracts
Abstract
Decade of insights: Bleomycin-induced pneumonitis and use of G-CSF in chemotherapy-treated germ cell testicular tumors and Hodgkin lymphoma—Real-world outcomes from an academic cancer center.Org: The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The James Cancer Hospital @ OSU Wexner Medical Center, Tha James Cancer Hospital and Solove Research Institute,
Abstract
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.Org: Moffitt Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Northwell Health, New Hyde Park, NY, Center for Cancer Care at White Plains Hospital, Yale School of Medicine,
Abstract
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Data Sciences, Dana-Farber Cancer Institute,
Abstract
Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
Chondrosarcoma: The OSU experience.Org: The Ohio State University Medical Center, The Ohio State University - James Cancer Hospital, Ohio State University James Cancer Hospital Department of Radiation Oncology, Ohio State University Hospital, The Ohio State University - James Cancer Hospital and Solove Research Institute,
Abstract
Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).Org: Ohio State University Wexner Medical Center, Adena Health System, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University James Cancer Hospital Department of Radiation Oncology,
Abstract
Clear cell sarcoma: The OSU experience.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Medical Center, The Ohio State University James Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University Wexner Medical Center,